419 related articles for article (PubMed ID: 16730565)
1. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
[TBL] [Abstract][Full Text] [Related]
2. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?
Higgins R; Kirklin JK; Brown RN; Rayburn BK; Wagoner L; Oren R; Miller L; Flattery M; Bourge RC;
J Heart Lung Transplant; 2005 Apr; 24(4):392-400. PubMed ID: 15797738
[TBL] [Abstract][Full Text] [Related]
3. Relationship between bridging with ventricular assist device on rejection after heart transplantation.
Pamboukian SV; Costanzo MR; Dunlap S; Rayburn B; Westfall AO; You ZY; Hung E; McLeod M; Heroux A
J Heart Lung Transplant; 2005 Mar; 24(3):310-5. PubMed ID: 15737758
[TBL] [Abstract][Full Text] [Related]
4. Attrition from heart transplant waiting list for patients on ventricular assist devices is not affected by desensitization strategies.
Gonzalez-Stawinski GV; Cook DJ; Smedira NG; Navia JL; Taylor DO; Yamani MH; Hoercher K; Starling RC; Banbury MK
Transplant Proc; 2007 Jun; 39(5):1571-2. PubMed ID: 17580190
[TBL] [Abstract][Full Text] [Related]
5. Sensitisation and post-transplant course after the implantation of ventricular assist device.
Malickaite R; Rucinskas K; Staneviciene A; Miniauskas S; Maneikiene V; Zuoziene G; Sirvydis V
Interact Cardiovasc Thorac Surg; 2009 Mar; 8(3):339-42; discussion 342-3. PubMed ID: 19098066
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
[TBL] [Abstract][Full Text] [Related]
7. Immunologic sensitization in recipients of left ventricular assist devices.
John R; Lietz K; Schuster M; Naka Y; Rao V; Mancini DM; Rose EA; Smith CR; Oz MC; Edwards NM; Itescu S
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):578-91. PubMed ID: 12658200
[TBL] [Abstract][Full Text] [Related]
8. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device.
Baran DA; Gass AL; Galin ID; Zucker MJ; Arroyo LH; Goldstein DJ; Prendergast T; Lubitz S; Courtney MC; Correa R; Chan M; Spielvogel D; Lansman SL
J Heart Lung Transplant; 2005 Nov; 24(11):1886-90. PubMed ID: 16297796
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
10. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
12. Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy.
Kirsch L; Timmermans T; Van Caenegem O; Gurne O; Noirhomme P; Jacquet LM; Latinne D; Poncelet AJ
Eur J Cardiothorac Surg; 2008 Aug; 34(2):268-74; discussion 274. PubMed ID: 18456505
[TBL] [Abstract][Full Text] [Related]
13. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3.
McOmber D; Ibrahim J; Lublin DM; Saffitz JE; Ong-Simon C; Mendeloff EN; Huddleston CB; Canter CE
J Heart Lung Transplant; 2004 May; 23(5):552-7. PubMed ID: 15135370
[TBL] [Abstract][Full Text] [Related]
14. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
15. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
[TBL] [Abstract][Full Text] [Related]
16. One hundred days or more bridged on a ventricular assist device and effects on outcomes following heart transplantation.
Robertson JO; Lober C; Smedira NG; Navia JL; Sopko N; Gonzalez-Stawinski GV
Eur J Cardiothorac Surg; 2008 Aug; 34(2):295-300. PubMed ID: 18539472
[TBL] [Abstract][Full Text] [Related]
17. The effect of ventricular assist devices on post-transplant mortality an analysis of the United network for organ sharing thoracic registry.
Patlolla V; Patten RD; Denofrio D; Konstam MA; Krishnamani R
J Am Coll Cardiol; 2009 Jan; 53(3):264-71. PubMed ID: 19147043
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
19. Comparative trial of immunoprophylaxis with RATG versus OKT3.
Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
[TBL] [Abstract][Full Text] [Related]
20. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
